Skip to contentSkip to filters

We use cookies for analytics.

Grant, Call number PAR-28-072

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

National Eye Institute

  • United States
  • Institution applies
  • Ophthalmology, Pharmacology and
Related content

About

The National Eye Institute supports preclinical development of a treatment for visual disorders. Teams use a milestone-driven exploratory phase and can progress a single candidate toward regulatory submission and future clinical testing.

Topics

Eligibility

Covers: Up to five years across both phases. R61 direct costs should rarely exceed USD 500,000 per year and R33 direct costs should not exceed USD 1 million per year.

The applicant must be a US institution.

simpler.grants.govfiles.simpler.grants.gov

Eligible US institutions include universities, research organizations, eligible businesses and other organizations named in the announcement. Foreign organizations and non-US components of US organizations cannot apply.

Source: simpler.grants.gov